Date: 2017-09-04
Type of information: Nomination
Compound: chief medical officer
Company: Eyevensys (France)
Therapeutic area: Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 4, 2017, Eyevensys announced the expansion of its executive team with the addition of Dr Ronald R. Buggage as its Chief Medical Officer. Dr Buggage brings more than 14 years’ experience from both large pharma and biotech companies having worked in senior development positions in the US and Europe. Dr Buggage will drive the company’s drug development strategy, overseeing clinical development programs for a broad range of ophthalmic indications based Eyevensys’ unique non-viral gene therapy EyeCET platform.
- Dr Buggage was most recently Division Medical Officer at Sanofi’s Ophthalmology Unit, responsible for the leadership and coordination of medical and scientific activities for its ophthalmology portfolio including development programs for ocular gene therapy. He also served as Chief Scientific Officer of Novagali Pharma, where he was responsible for the global clinical and regulatory strategy; Novagali Pharma was successfully acquired by Santen. Prior to moving to France, Dr Buggage held various positions of increasing clinical development responsibility at Novartis and Pfizer. Dr Buggage obtained his MD at UCLA School of Medicine, specializing in ophthalmology at Emory, and completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health (NIH).
Financial terms:
Latest news:
Is general: Yes
